Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Sacituzumab tirumotecan in Renal Medullary Carcinoma: NCT07438626 Clinical Landscape Report 2026
18 September 2026
NCT07438626 clinical landscape for Renal Medullary Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Progesterone in Endometrial Endometrioid Adenocarcinoma: NCT07436793 Clinical Landscape Report 2026
18 September 2026
NCT07436793 clinical landscape for Endometrial Endometrioid Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
TAK-505 in Locally Advanced Malignant Solid Neoplasm: NCT07436728 Clinical Landscape Report 2026
18 September 2026
NCT07436728 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Enzomenib in Multiple Myeloma: NCT07444268 Clinical Landscape Report 2026
18 September 2026
NCT07444268 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Perflutren lipid microsphere in Soft Tissue Sarcoma: NCT07436364 Clinical Landscape Report 2026
18 September 2026
NCT07436364 clinical landscape for Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rapcabtagene autoleucel in Large B-cell lymphoma: NCT07443137 Clinical Landscape Report 2026
18 September 2026
NCT07443137 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tunlametinib in NRAS Mutant Melanoma: NCT07445022 Clinical Landscape Report 2026
18 September 2026
NCT07445022 clinical landscape for NRAS Mutant Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SPGL008 in Non-Muscle Invasive Bladder Neoplasms: NCT07445308 Clinical Landscape Report 2026
18 September 2026
NCT07445308 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Dexmedetomidine Hydrochloride in Anesthesia: NCT07445451 Clinical Landscape Report 2026
18 September 2026
NCT07445451 clinical landscape for Anesthesia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HWK-007 in Endometrial Carcinoma: NCT07444814 Clinical Landscape Report 2026
18 September 2026
NCT07444814 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Soft Tissue Sarcoma: NCT07444619 Clinical Landscape Report 2026
18 September 2026
NCT07444619 clinical landscape for Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD45BE-HSPC in Hodgkin's Lymphoma: NCT07451054 Clinical Landscape Report 2026
18 September 2026
NCT07451054 clinical landscape for Hodgkin's Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.